Dr. Reddys Labs (RDY) Announces U.S. Launch of Generic Nitrostat Tabs

August 29, 2016 6:18 AM EDT
Get Alerts 500124 Hot Sheet
Trade 500124 Now!
Join SI Premium – FREE

News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.

Dr. Reddy’s Laboratories Ltd (NYSE: RDY) announced that it has launched Nitroglycerin sublingual tablets USP, 0.3 mg, 0.4 mg and 0.6 mg, a therapeutic equivalent generic version of Nitrostat® (Nitroglycerin) sublingual tablets in the US market on August 26, 2016, having been approved by the United States Food & Drug Administration (USFDA).

The Nitrostat® (Nitroglycerin) sublingual tablet brand had U.S. sales of approximately $ 108 Million MAT for the most recent twelve months ending in March 2016 according to IMS Health*.

Dr. Reddy’s Nitroglycerin sublingual tablets USP, 0.4 mg is available in bottle count size of 100 and a bundle of 4 bottles of count size 25, Nitroglycerin sublingual tablets USP, 0.3mg is available in bottle count size of 100 and the Nitroglycerin sublingual tablets USP, 0.6mg is available in bottle count size of 100.

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In

Related Categories

Corporate News, Management Comments

Add Your Comment